North America Chronic Lymphocytic Leukemia Therapeutics Market

North America chronic lymphocytic leukemia therapeutics market is estimated to grow at a CAGR of 8.7% during the forecast period (2022-2029) to reach a market value of USD  YY million by 2029.

The North American region dominated the global chronic lymphocytic leukemia therapeutics market in 2020 owing to the rising incidence of CLL coupled with a high rate of mortality, demonstrating the unmet market need for better therapeutics. 

According to cancer.net, in 2021, there are 21,250 people of all ages (13,040 men and boys and 8,210 women and girls) in the United States will be diagnosed with CLL. While it can occur at any age, CLL is more common in older adults. The average age at diagnosis is around 70. CLL is uncommon in people younger than 40 and is very rare in children. CLL is the most common type of leukemia in adults older than 19, accounting for 38% of all leukemia diagnoses.

The rate of new cases of chronic lymphocytic leukemia was 4.9 per 100,000 men and women per year. The death rate was 1.1 per 100,000 men and women per year. These rates are age-adjusted and based on 2014–2018 cases and 2015–2019 deaths.

Therefore, the National Health Federation in the United States has been awarding grants and fellowships to support innovative research intended for finding better treatments and cures for several bleeding disorders.

Such research has led to vital insights into improved factor replacement therapies, along with more accurate chronic lymphocytic leukemia therapeutics methods, and therefore definitely a greater understanding of the genetic basis of the disease. Hence, owing to the rising prevalence of the disease along with the growing initiatives by several organizations are driving the market growth in the region. 

Doctors do a variety of tests to diagnose CLL. These tests look for specific features in the leukemia cells and genetic differences. Changes such as the position of chromosomes and mutations are common in CLL. The results help doctors decide on the best-individualized treatment plans.

Many companies in the region are also focusing on developing breakthrough products for the treatment of chronic lymphocytic leukemia to maintain their competitive advantage and penetrate new regional markets. Chemotherapy is thus considered the main treatment option for most individuals with Leukemia. Additionally, the increase in funding for companies involved in research related to leukemia is expected to boost the market in the region.

Also, an increase in the approvals from regulatory bodies along with ongoing research activities by the major companies in the United States are likely to contribute the largest share of revenue in the region propelling the global chronic lymphocytic leukemia market.

For instance, in November 2019, AstraZeneca PLC  received US Food and Drug Administration (FDA) approval for its Calquence (acalabrutinib) to treat adult patients with CLL which is expected to impel the global Chronic lymphocytic leukemia market growth.

 Furthermore, few key players are entering into partnerships to develop and increase their market position globally. 

Thus, rising awareness campaigns and supportive initiatives plan by the government to commence early screening of neonates, which is expected to boost the market of chronic lymphocytic leukemia therapeutics in the region.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com